Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose escalating HM11260C versus placebo in adults with type 2 diabetes mellitus
NL-OMON34301Phase 2Active, not recruiting
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jun 2010
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing HM11260C escalating-dose arm with Placebo arm (2 arms). Primary endpoints: Safety and tolerability of single escalating subcutaneous doses of HM11260C, Pharmacokinetic profile of HM11260C and 1 more. Started Jun 2010; status: active, not recruiting.
02
Drugs
efpeglenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON34301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34301.